View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
December 1, 2013

Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOX®

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of a sales milestone for TRISENOX® (arsenic trioxide).

By Vinod

TRISENOX was acquired from CTI by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva.

The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI is eligible to receive up to an additional $95 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable.

Content from our partners
Unlocking growth through hybrid cloud: 5 key takeaways
How businesses can safeguard themselves on the cyber frontline
How hackers’ tactics are evolving in an increasingly complex landscape

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU